Answers are grounded in this paper and cite their sources.
Adult IDH-wildtype glioblastoma remains largely resistant to immunotherapy, even though selected patients develop measurable immune responses. Treatment begins within a rapidly changing perioperative endocrine and metabolic environment. Glioblastoma resection, dexamethasone, acute stress, dysglycemia, altered nutrition, infection, and tissue repair can reshape systemic metabolism and immune-cell composition within hours, while residual glioblastoma tissue undergoes spatially heterogeneous myeloid remodeling over days to weeks. This Review evaluates perioperative exposures, routine blood measures, circulating multi-omics, extracellular vesicles, paired blood-tissue analyses, and mechanistic studies of myeloid immunometabolism in adult IDH-wildtype glioblastoma. Dexamethasone exposure, glycemic status, and blood-derived inflammatory indices are clinically accessible, but most reported associations remain confounded and do not define treatment thresholds. Longitudinal lipidomic, metabolomic, proteomic, and cellular measurements can detect treatment-related state transitions; without standardized timing and tissue anchoring, however, their biological sources remain uncertain. Mechanistic studies connect glucose-lactate signaling, histone lactylation, lipid handling, hypoxia, and cell-of-origin transitions with myeloid suppression, but therapeutic evidence is still largely preclinical. We therefore propose an exposure-time-compartment-biology-decision framework for glioblastoma biomarker development. Its present role is to strengthen trial stratification, confounding control, and pharmacodynamic interpretation, not to justify unvalidated dexamethasone adjustment, immunotherapy selection, or vaccine timing at the bedside.
No takes yet. Share an insight, caveat, or question.
Zhan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: